ABL has become one of the BioHealth Capital Region’s most trusted CDMOs by turning early scientific ideas into real clinical progress. Their patient-first, partnership-driven approach helps innovators move confidently from concept to care.
In every therapeutic journey, there is a moment when the science becomes something more than a concept. It becomes a possibility. That moment doesn’t happen by accident. It happens because a trusted partner knows how to take a company’s vision, protect it, scale it, and move it toward the patient with purpose.
In the BioHealth Capital Region, few organizations embody this better than ABL; a CDMO that has built a reputation for doing things differently. ABL’s approach is rooted in a simple but powerful philosophy: patients first, partners always.
A Different Kind of CDMO Partnership
The CDMO landscape has grown significantly in the last decade, but not all players take the same approach. Some focus exclusively on scale. Some specialize in narrow modalities. Others offer menus of a-la-carte services that are transactional by design.
ABL stands apart because its foundation is mission-driven. Born and built in Maryland, the company has spent decades supporting some of the most ambitious vaccine, gene therapy, biologics, and infectious disease programs in the world. One of the core drivers to their success is that their teams don’t talk about clients or customers, they talk about partners, the people and programs they walk alongside from early development through execution.
Where some CDMOs say “we’ll take it from here,” ABL says “let’s do this together.”
It’s why early-stage innovators feel safe handing over their first-in-human assets, and why established biopharma groups continue to trust ABL with their most critical programs.
A Partner to Organizations of Every Size
The beauty of ABL’s structure is that it’s built to serve across the spectrum. The BioHealth Capital Region is home to global enterprises, growing mid-sized companies, and a rapidly expanding constellation of early-stage biotech startups. ABL has intentionally built a model that supports all three.
Startups often need a CDMO that provides guidance as much as production. They need a team that helps refine processes, navigate regulatory expectations, validate assays, troubleshoot upstream or downstream challenges, and build a roadmap that makes sense for their resources. ABL shines in this space by not just doing the work, but helping young companies understand it.
At the same time, ABL has the infrastructure, experience, and technical depth to support large organizations with sophisticated program demands, complex quality requirements, and long-term manufacturing strategies. Their teams know how to scale efficiently, maintain rigorous compliance, and seamlessly integrate with a sponsor’s technical and quality groups. For established companies, ABL becomes a trusted extension of in-house expertise, offering the flexibility and responsiveness that large biopharma often struggles to find.
This flexibility is exactly why ABL continues to be selected for multimillion-dollar contracts and government partnerships, including recent awards from agencies like NINDS to support the development of high-impact therapeutics across critical disease areas.
ABL and Ascend Advanced Therapies announced a merger last year, which added late phase and commercial manufacturing capabilities to ABL’s portfolio – creating a truly end-to-end platform solution as a drug development partner from discovery through commercialization.
Putting the Human Back Into the Process
Ask anyone at ABL what motivates their work, and you’ll hear a common theme: the patient.
The company doesn’t just support therapeutic programs, they internalize the human impact behind each one. It changes how they approach timelines. It shapes how they handle deviations or risk assessments. It influences how they communicate with sponsors during critical decision points. And it defines how they build internal culture, one where scientific rigor and compassion exist side by side.
This is why so many partners describe ABL not as a vendor, but as an extension of their own team.
Because when a therapy finally reaches a clinical milestone, or when a batch is released that will make its way into a trial participant’s hands, ABL celebrates it the same way the sponsor does, as a victory for the patient.
And ABL’s impact isn’t limited to patients, it’s shaping the talent landscape of the entire BioHealth Capital Region as well. As the company continues to expand, it fuels local job creation and consistently invests in regional talent, offering long-term growth for Maryland’s life sciences community.
From Concept to Care: The ABL Promise
Innovation doesn’t move in straight lines. It takes resilience, collaboration, and the right partners who understand the stakes. ABL has become one of the region’s most trusted CDMOs because they take that responsibility seriously. From early development through nonclinical support, GMP manufacturing, quality oversight, and analytical services, their team delivers the expertise and empathy needed to bring transformative ideas to life.
For companies across the BioHealth Capital Region and beyond, ABL is proving that the journey from concept to care is faster, smoother, and more impactful when pursued together, and always with the patient at the center.
ABL’s message to the industry is unmistakable: “We will meet you where you are, and we will grow with you.”
